Drug Trial Radar · NCT06957327
A Study of ERAS-601 in People With Chordoma
Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12
Actual
Start
Apr 25, 2025
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.
Conditions
- Chordoma
Interventions
ERAS-601Drug
ERAS-601 40mg BID, 3-weeks on 1-week off (3/1), as monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Benefit Rate (Phase Ib)Time frame: 1 year
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey
Memorial Sloan Kettering Cancer Center - Suffolk (Limited Protocol Activities)
Commack, New York
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.